Details
Category: Volume 07 Issue 02 February 2019
Hits: 1462

Title: Effect of Ormeloxifene on Mastalgia and Fibrocystic breast diseases

Authors: Dr Vinita Kumari, Prof (Dr) Renu Rohatgi

 DOI: https://dx.doi.org/10.18535/jmscr/v7i2.171

Abstract

Introduction: The majority of breast lesions are benign. Among benign lesions the commonest are fibrocystic disease and mastalgia. Ormeloxifene is a selective estrogen receptor modulator (SERM) with a weak agonist on endometrium and strong antagonist on breast and is used in treatment of benign breast diseases.

Material and Methods: 156   Patients coming with complains of breast pain and /or nodularity in the age group of 20 to 45 years was included in the study. Visual analogue scale was used for pain assessment and for assessment of nodularity Lucknow Cardiff Scale was used.

Observation and Result: At first follow up visit(2nd week) 25% had pain score of 2,  36% with pain score 4 and 37% with pain score 6.but at the end of treatment only 3.8% ,2.5% and 3.8% had score 2,4,and 6 respectively.

Regarding Nodularity status at initial visit 38 (24.35%) patients had grade 1 and 2 nodularity and 118(75.64%) had grades 3, 4 and 5 nodularity. At the end of follow up study 93% had grade 1 and 2 nodularity and only 10 (6.4%) had grade 3,4 and 5 nodularity.

Conclusion: Ormeloxifene is an effective drug for treatment of breast pain and nodularity.

References

  1. Kotepui M, Piwkham D, Chupeerach C, Songsri A, Charoenkijkajorn L. Epidemiology and histopathology of benign breast diseases and breast cancer in southern Thailand. Eur J Gynaecol Oncol. 2014;35(6):670–75. [PubMed]
  2. Kaur N, Agarwal N, Panwar P, Mishra K. Clinicopathologic profile of benign breast conditions in indian women: prospective study based on aberrations of normal development and involution classification. World J Surg. 2012;36(9): 2252–58. [PubMed]
  3. Santen RJ. Endotext [Internet] South Dartmouth (MA): MDText.com, Inc; 2000 [cited 2015 Jul 10]. Benign Breast Disease in Women. In: De Groot LJ, Beck-Peccoz P, Chrousos G, Dungan K, Grossman A, Hershman JM, et al., editors. Available from: http://www.ncbi.nlm.nih.gov/books/NBK278994/
  4. Asch RH, Greenblatt RB. The use of an impeded androgen – Danazol – In the management of benign breast disorders. Am J ObstetGynecol 1977;127:130-4.
  5. Mansel RE, Preece PE, Hughes LE. A double blind trial of the prolactin inhibitor bromocriptine in painful benign breast disease. Br J Surg 1978;65:724-7.
  6. Srivastava A, Mansel RE, Arvind N, Prasad K, Dhar A, Chabra A. Evidence-based management of mastalgia: A meta-analysis of randomised trials. Breast. 2007;16:503–12.
  7. Dhar A, Srivastava A. Role of centchroman in regression of mastalgia and fibroadenoma. World J Surg. 2007;31:1178–84.
  8. Fentiman IS, Caleffi M, Hamed H, Chaudary MA. Dosage and duration of tamoxifen treatment for mastalgia: A controlled trial. Br J Surg 1988;75:845-6
  9. Mansel RE, Goyal A, Preece P, Leinster S, Maddox PR, Gateley C, et al. European randomized, multicenter study of goserelin (Zoladex) in the management of mastalgia. Am J ObstetGynecol 2004;191:1942-9.
  10. Barros AC, Mottola J, Ruiz CA, Borges MN, Pinotti JA. Reassurance in the Treatment of Mastalgia. Breast J 1999;5:162-165. 12.. Hadi MS. Sports Brassiere: Is It a Solution for Mastalgia? Breast J 2000;6:407-409.

Corresponding Author

Dr Vinita Kumari

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.